Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics

Am J Hematol. 2015 Feb;90(2):E29-30. doi: 10.1002/ajh.23884. Epub 2014 Nov 19.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Antibiotics, Antineoplastic / therapeutic use*
  • Clinical Trials as Topic
  • Cytogenetic Analysis
  • Daunorubicin / therapeutic use*
  • Drug Administration Schedule
  • Female
  • Genotype
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics*
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / pathology
  • Male
  • Middle Aged
  • Remission Induction
  • Retrospective Studies
  • Survival Analysis

Substances

  • Antibiotics, Antineoplastic
  • Daunorubicin